24/08/2009 (Agence Europe) - The European Commission has approved Xolair produced by Novartis as add-on therapy for severe persistent allergic asthma in children aged 6 to 11 years, the Swiss pharmaceutical group announced on Monday 24 August. Xolair had already been approved in 2005 for children aged 12 and over. Asthma is a chronic lung disease which affects 10% of children in Europe, Novartis points out, adding that severe forms of the disease remain uncontrolled in more than 50% of...